secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2026-07-20T20:06:12+00:00
Accession:  0001104659-26-085061
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia signs agreement to sell SimpliDerm business for up to $11M, focuses on NXT-41x launch
--------------------------------------------------------------------------------

- Total consideration up to $11M: $8M cash at closing plus up to $3M in technology transfer and commercial milestone payments over 18 months.
- Closing expected in H2 2026, subject to customary conditions; buyer is Cellution Biologics Inc.
- Proceeds provide non-dilutive capital to advance NXT-41x toward clearance and commercial launch in 2027.
- Divestiture sharpens Elutia's focus on the $1.5B plastic and reconstructive surgery market with NXT-41x.
- SimpliDerm is a human acellular dermis product for breast reconstruction; sale completes strategic review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926085061/0001104659-26-085061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926085061/tm2620864d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-085061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer